models.All patients provided informed consent, and the study was approved by the local ethics committee.Results: Approximately 66% of participants reported poor sleep quality (PSQI>5), and 41% had clinically significant insomnia (ISI15).Sleep disturbances were significantly associated with reduced global health status and impaired physical, emotional, cognitive, and social functioning (all p<0.001).Patients receiving chemotherapy reported higher insomnia severity and poorer sleep quality than those on endocrine or targeted therapies.The number of chemotherapy cycles positively correlated with insomnia severity (=0.23,p=0.002).Conclusions: Sleep disturbances are common in BC patients receiving systemic treatment and are strongly associated with reduced HRQoL.Systematic screening and targeted interventions for sleep disturbances should be integrated across the continuum of care, as these disturbances can compromise patients' HRQoL and functional outcomes.Legal entity responsible for the study: The authors.
Reda et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: